Bioorg Med Chem Lett. 2008 Sep 1;18(17):4907-12. doi: 10.1016/j.bmcl.2008.06.042. Epub 2008 Jun 18.

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

Source

ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.

Abstract

Novel N(9)-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N(9) on the purine core which projects hydrophobic substituents into the selectivity pocket at the rear of the ATP site. Their synthesis was achieved through a Horner-Wadsworth-Emmons reaction of N(9)-phosphorylmethylpurines and substituted benzaldehydes or Heck reactions between 9-vinyl purines and aryl halides. Most compounds are potent inhibitors of both Src and Abl kinase, and several possess good oral bioavailability.

PMID:: 18691885; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Chemical Information

BindingDB

Supplemental Content

Save items

Related citations in PubMed

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. [J Med Chem. 2009]
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Huang WS, Zhu X, Wang Y, Azam M, Wen D, Sundaramoorthi R, Thomas RM, Liu S, Banda G, Lentini SP, et al. J Med Chem. 2009 Aug 13; 52(15):4743-56.
Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro. [Leuk Lymphoma. 2009]
Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.
Liu H, Li H, Feng Z, Tai J, Meng Y, Wang H, Xin H, Zhang S, Zuo M, Zhang Y, et al. Leuk Lymphoma. 2009 Mar; 50(3):437-46.
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. [ChemMedChem. 2009]
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M. ChemMedChem. 2009 Jan; 4(1):118-26.
Review Last findings on dual inhibitors of abl and SRC tyrosine-kinases. [Mini Rev Med Chem. 2007]
Review Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Schenone S, Manetti F, Botta M. Mini Rev Med Chem. 2007 Feb; 7(2):191-201.
Review An update on dual Src/Abl inhibitors. [Future Med Chem. 2012]
Review An update on dual Src/Abl inhibitors.
Musumeci F, Schenone S, Brullo C, Botta M. Future Med Chem. 2012 Apr; 4(6):799-822.

See reviews... See all...

Cited by 1 PubMed Central article

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. [Cancer Cell. 2009]
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al. Cancer Cell. 2009 Nov 6; 16(5):401-12.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
BioAssay
PubChem BioAssay experiments on the biological activities of small molecules that cite the current articles. The depositors of BioAssay data provide these references.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Bioorg Med Chem Lett. 2008 Sep 1 ;18(17):4907-12. doi: 10.1016/j.bmcl.2008.06.042. Epub 2008 Jun 18 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Chemical Information

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information